Baseline patient’s characteristics
Variable . | N . | % . |
---|---|---|
Age | ||
<70 y | 176 | 74.3 |
≥70 y | 61 | 25.7 |
Sex | ||
Female | 128 | 54.0 |
Male | 109 | 46.0 |
Race/ethnicity | ||
Non-Hispanic white | 192 | 81.0 |
Hispanic white | 14 | 5.9 |
African American | 18 | 7.6 |
Other | 13 | 5.5 |
Tumor stage | ||
Stage I-II (early stage) | 58 | 24.5 |
Stage III-IV (advanced stage) | 179 | 75.5 |
ECOG performance status* | ||
0 | 154 | 65.0 |
1 | 74 | 31.2 |
2 | 9 | 3.8 |
B symptoms* | ||
Non-B symptoms | 195 | 82.3 |
B symptoms | 42 | 17.7 |
LDH* | ||
Normal LDH | 192 | 81.0 |
Elevated LDH | 45 | 19.0 |
Number of extranodal site | ||
1 | 130 | 54.9 |
≥2 | 107 | 45.1 |
Unknown | 1 | 0.4 |
Bone marrow involvement | ||
Negative | 144 | 60.8 |
Positive | 64 | 27.0 |
Unknown | 29 | 12.2 |
MALT-IPI score | ||
0 | 40 | 16.9 |
1 | 118 | 49.8 |
2-3 | 79 | 33.3 |
Variable . | N . | % . |
---|---|---|
Age | ||
<70 y | 176 | 74.3 |
≥70 y | 61 | 25.7 |
Sex | ||
Female | 128 | 54.0 |
Male | 109 | 46.0 |
Race/ethnicity | ||
Non-Hispanic white | 192 | 81.0 |
Hispanic white | 14 | 5.9 |
African American | 18 | 7.6 |
Other | 13 | 5.5 |
Tumor stage | ||
Stage I-II (early stage) | 58 | 24.5 |
Stage III-IV (advanced stage) | 179 | 75.5 |
ECOG performance status* | ||
0 | 154 | 65.0 |
1 | 74 | 31.2 |
2 | 9 | 3.8 |
B symptoms* | ||
Non-B symptoms | 195 | 82.3 |
B symptoms | 42 | 17.7 |
LDH* | ||
Normal LDH | 192 | 81.0 |
Elevated LDH | 45 | 19.0 |
Number of extranodal site | ||
1 | 130 | 54.9 |
≥2 | 107 | 45.1 |
Unknown | 1 | 0.4 |
Bone marrow involvement | ||
Negative | 144 | 60.8 |
Positive | 64 | 27.0 |
Unknown | 29 | 12.2 |
MALT-IPI score | ||
0 | 40 | 16.9 |
1 | 118 | 49.8 |
2-3 | 79 | 33.3 |
Adjust study site as random effect. NE, not estimable.
ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; MALT-IPI, Mucosa associated lymphoid tissue International Prognostic Index.
Missing values included in normal/no symptoms categories.